Tandospirone
Title: Tandospirone
CAS Registry Number: 87760-53-0
CAS Name: (3aa,4b,7b,7aa)-Hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-methano-1H-isoindole-1,3(2H)-dione
Additional Names: (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3-bicyclo[2.2.1]heptanedicarboximide
Molecular Formula: C21H29N5O2
Molecular Weight: 383.49
Percent Composition: C 65.77%, H 7.62%, N 18.26%, O 8.34%
Literature References: Serotonin (5-HT1A) receptor agonist. Prepn: K. Ishizumi et al., EP 82402; eidem, US 4507303 (1983, 1985 both to Sumitomo); idem et al., Chem. Pharm. Bull. 39, 2288 (1991). Behavioral pharmacology: C. A. Sannerud et al., Drug Alcohol Depend. 32, 195 (1993). Clinical efficacy in treatment of bulimia: H. Tamai et al., Int. J. Obes. 14, 289 (1990). Clinical evaluation of potential adverse effects: M. Suzuki et al., Jpn. J. Psychopharmacol. 13, 213 (1993); of abuse liability: S. M. Evans et al., J. Pharmacol. Exp. Ther. 271, 683 (1994). Review of pharmacology: P. A. Seymour et al., Prog. Clin. Biol. Res. 361, 453-460 (1990).
Properties: Crystals from toluene/n-hexane, mp 112-113.5°.
Melting point: mp 112-113.5°
 
Derivative Type: Citrate
CAS Registry Number: 112457-95-1
Manufacturers' Codes: SM-3997
Trademarks: Sediel (Sumitomo)
Molecular Formula: C21H29N5O2.C6H8O7
Molecular Weight: 575.61
Percent Composition: C 56.34%, H 6.48%, N 12.17%, O 25.02%
Properties: mp 169.5-170°.
Melting point: mp 169.5-170°
 
Derivative Type: Hydrochloride
Molecular Formula: C21H29N5O2.HCl
Molecular Weight: 419.95
Percent Composition: C 60.06%, H 7.20%, N 16.68%, O 7.62%, Cl 8.44%
Properties: Crystals from isopropanol, mp 227-229°.
Melting point: mp 227-229°
 
Therap-Cat: Anxiolytic; antidepressant.
Keywords: Antidepressant; Anxiolytic; Arylpiperazines; Serotonin Receptor Agonist.

Others monographs:
TriazolamLeonurineChromium CarbonylOrlon®
4-Hydroxyisophthalic AcidMetaclazepamTizanidineMethanesulfonic Acid
TriethylenemelamineArsenamideGlyphosateNeurine
Cyclodrine3-PentadecylcatecholGliotoxinSodium Bisulfite
©2016 DrugLead US FDA&EMEA